Quality of blood pressure control and risk of cerebral bleeding in patients with oral anticoagulation

Acta Medica Austriaca

Volumn 30, Issue 1, 2003, Pages 6-9

  Huber, J ^c   Stöllberger, Claudia ^b   Finsterer, J ^c   Schneider, Barbara ^a   Langer Th ^c  

^a UNIVERSITY OF VIENNA   (Austria)

^b Second Medical Department   (Austria)

^c NONE

Author keywords

Arterial hypertension; Cerebral bleeding; Oral anticoagulation

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MINOXIDIL; NITRATE; VASODILATOR AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; FEMALE; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, ORAL; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CEREBRAL HEMORRHAGE; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; REFERENCE VALUES; RISK FACTORS; TIME FACTORS;

EID: 0037275027     PISSN: 03038173     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1563-2571.2003.02048.x     Document Type: Article

References (39)

1. Adhiyaman V, Kamalakannan D, Oke A, Shah IU, White AD: Underutilization of antithrombotic therapy in atrial fibrillation. J R Soc Med 2000;93: 138-140.
2. Albers GW, Bittar N, Young L, Hattemer CR, Gandhi AJ, Kemp SM, Hall EA, Morton DJ, Yim J, Vlasses PH: Clinical characteristics and management of acute stroke in patients with atrial fibrillation admitted to US university hospitals. Neurology 1997;48: 1598-1604.
3. Albers GW, Yim JM, Belew KM, Bittar N, Hattemer CR, Phillips BG, Kemp S, Hall EA, Morton DJ, Vlasses PH: Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med 1996;156: 2311-2316.
4. Alderman M, Arakawa K, Beilin L, Chalmers J, Erine S, Hamet P: World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999;17: 151-183.
5. Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994;154: 1449-1457.
6. Bath PMW, Prasad A, Brown MM, MacGregor GA: Survey of use of anticoagulation in patients with atrial fibrillation. Br Med J 1993;307:1045.
7. Beyth RJ, Quinn LM, Landefeld CS: Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;105: 91-99.
8. Brass LM, Krumholz HM, Scinto JM, Redford M: Warfarin use among patients with atrial fibrillation. Stroke 1997;28: 2382-2389.
9. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C: for the CAFA Study Coinvestigators. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18: 349-355.
10. Dawson I, van Bockel JH, Ferrari MD, van der Meer FJ, Brand R, Terpstra JL: Ischemic and hemorrhagic stroke in patients on oral anticoagulants after reconstruction for chronic lower limb ischemia. Stroke 1993;24: 1655-1663.
11. Du X: Prevalence, treatment, control, and awareness of high blood pressure and the risk of stroke in Northwest England. Prev Med 2000;30: 288-294.
12. EAFT (European Atrial Fibrillation Trial) Study Group: Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342: 1255-1262.
13. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ, Rickles FR, Shabetai R, Deykin D: for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators: Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327: 1406-1412.
14. Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, White RH: for the Warfarin Optimized Outpatient Follow-up Study Group: Risk factors for complications of chronic anticoagulation. A multicenter study. Ann Intern Med 1993;118: 511-520.
15. Flaker GC, McGowan DJ, Boechler M, Fortune G, Gage B: Underutilization of antithrombotic therapy in elderly rural patients with atrial fibrillation. Am Heart J 1999;137: 307-312.
16. Gasse C, Hense HW, Stieber J, Doring A, Liese AD, Keil U: Assessing hypertension management in the community: trends of prevalence, detection, treatment, and control of hypertension in the MONICA Project, Augsburg 1984-95. J Hum Hypertens 2001;15: 27-36.
17. Gitter MJ, Jaegger TM, Petterson TM, Gersh BJ, Silverstein MD: Bleeding and thromboembolism during anticoagulant therapy: A population-based study in Rochester, Minnesota. Mayo Clin Proc 1995;70: 725-733.
18. Go AS, Hylek EM, Phillips KA, Borowsky LH, Henault LE, Chang Y, Selby JV, Singer DE: Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation 2000;102: 11-13.
19. Hart RG, Boop BS, Anderson DC: Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995;26: 1471-1477.
20. Launbjerg J, Egeblad H, Heaf J, Nielsen NH, Fugleholm AM, Ladefoged K: Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients. Intern Med 1991;229: 351-355.
21. Lip GYH, Golding DJ, Nazir M, Beevers DG, Child DL, Fletcher RI: A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br J Gen Pract 1997;47: 285-289.
22. Munschauer FE, Priore RJ, Hens M, Castilone A: Thromboembolism prophylaxis in chronic atrial fibrillation. Practice patterns in community and tertiary-care hospitals. Stroke 1997;28: 72-76.
23. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, DÁngelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S: Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996;348: 423-428.
24. Perez I, Melbourn A, Kalra L: Use of antithrombotic measures for stroke prevention in atrial fibrillation. Heart 1999;82: 570-574.
25. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B: Placebocontrolled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK Study. Lancet 1989;1(8631): 175-179.
26. Prencipe M, Casini A R, Santini M, Ferretti C, Scaldaferri N, Culasso F: Prevalence, awareness, treatment and control of hypertension in the elderly: results from a population survey. J Hum Hypertens 2000;14: 825-830.
27. Schmidt R, Reinhart B, Schumacher M, Hayn M, Schmidt H, Fazekas F, Niederkorn K, Horner S, Lechner H, Offenbacher H, Eber B, Weinrauch V, Auer-Grumbach P, Kleinert G, Roob G, Kostner GM, Esterbauer H: Prevalence and risk factors in the population of Graz (Austrian Stroke Prevention Study). Wien Med Wochenschr 1997;147: 36-40.
28. Stafford RS, Singer DE: Recent national patterns of warfarin use in atrial fibrillation. Circulation 1998;97: 1231-1233.
29. Steffensen FH, Kristensen K, Ejlersen E, Dahlerup JF, Sorensen HAT: Major hemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort. J Intern Med 1997;242: 497-503.
30. Stein AD, Stoyanovsky V, Mincheva V, Dimitrov E, Hodjeva D, Petkov A, Tsanova V: Prevalence, awareness, treatment and control of hypertension in a working Bulgarian population. Eur J Epidemiol 2000;16: 265-270.
31. Stergiou GS, Thomopoulou GC, Skeva II, Mountokalakis TD: Prevalence, awareness, treatment, and control of hypertension in Greece: the Didima study. Am J Hypertens 1999;12: 959-965.
32. Stöllberger C, Finsterer J, Slany J: für die CORSurvey Erhebung: Antithrombotische Therapie bei Vorhofflimmem und zusätzlichen Schlaganfall-/Embolie-Risikofaktoren. Z Kardiol 1999;88: 442-447.
33. Stroke Prevention in Atrial Fibrillation Investigators: Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991;84: 527-539.
34. Stroke Prevention in Atrial Fibrillation Study Group Investigators: Preliminary report of the stroke prevention in atrial fibrillation study. N Engl J Med 1990;322: 863-868.
35. The Stroke Prevention in Atrial Fibrillation Investigators: Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996;156: 409-416.
36. Van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E: Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 1996;76: 12-16.
37. Wehinger C, Stöllberger C, Länger T, Schneider B, Finsterer J: Evaluation of risk factors for stroke/embolism and of complications due to anticoagulant therapy in atrial fibrillation. Stroke 2001;32: 2246-2252.
38. Wensley S, Keir S, Caine S, MacMahon M: Additional risk factors in atrial fibrillation patients not receiving warfarin. Age Ageing 1999;28: 355-357.
39. White RH, McBurnie MA, Manolio T, Furberg CD, Gardin JM, Kittner SJ, Bovill E, Knepper L: Oral anticoagulation inpatients with atrial fibrillation: adherence with guidelines in an elderly cohort. Am J Med 1999;106: 165-171.